Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Not Available].

A Kavanaugh1

  • 1Department of Internal Medicine, The University of Texas, Southwestern Medical Center, Dallas, Texas, USA.

Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy
|February 1, 1997
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Psoriatic arthritis: improvement in outcomes but persistent sex difference - 5-year follow-up study of a Norwegian outpatient clinic population.

Scandinavian journal of rheumatology·2023
Same author

Psoriasis and metabolic syndrome: implications for the management and treatment of psoriasis.

Journal of the European Academy of Dermatology and Venereology : JEADV·2022
Same author

Perceived influence of health status on sexual activity in patients with psoriatic arthritis.

Scandinavian journal of rheumatology·2020
Same author

Correlation of serum protein biomarkers with disease activity in psoriatic arthritis.

Expert review of clinical immunology·2020
Same author

Techniques for improving the initial strength of the tibial tray-cement interface bond.

The bone & joint journal·2019
Same author

Secukinumab provides sustained PASDAS-defined remission in psoriatic arthritis and improves health-related quality of life in patients achieving remission: 2-year results from the phase III FUTURE 2 study.

Arthritis research & therapy·2018
Same journal

Ustekinumab Biosimilars versus Reference Ustekinumab for Moderate-to-Severe Plaque Psoriasis: A Pre-switch Systematic Review and Meta-analysis.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2026
Same journal

Correction: Mirikizumab as Induction and Maintenance Therapy in Chinese Patients with Ulcerative Colitis: A Subpopulation Analysis of the Randomized, Global Phase 3 LUCENT-1 and LUCENT-2 Trials.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2026
Same journal

Gene Therapy Strategies for Uveal Melanoma: Adeno-associated Virus Delivery Challenges and Translational Opportunities.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2026
Same journal

Review of Quality Attributes and Analytical Methods Used for Comparative Analytical Assessment of Monoclonal Antibodies as Part of Successful Biosimilar Approvals in the United States and European Union.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2026
Same journal

Impact of Repeated Antigen Exposure on Humoral Tolerance: Antidrug Antibodies After Single-Dose Versus Multi-dose Adalimumab.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2026
Same journal

An Overview and Trend Analysis of Biosimilar Approvals in China.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2026
See all related articles

Targeting adhesion receptors offers a novel therapy for systemic inflammatory diseases like rheumatoid arthritis. This antiadhesion strategy may block inflammatory cell recruitment and modulate immune cell function, potentially halting disease progression.

Area of Science:

  • Immunology
  • Rheumatology
  • Cell Biology

Background:

  • Systemic inflammatory diseases, such as rheumatoid arthritis, involve complex cellular interactions.
  • Adhesion receptors play a critical role in recruiting and activating immune cells at inflammatory sites like the synovium.
  • Targeting these receptors presents a potential therapeutic strategy for autoimmune and inflammatory conditions.

Purpose of the Study:

  • To explore the therapeutic potential of targeting adhesion receptors for systemic inflammatory diseases.
  • To review the mechanisms by which antiadhesion therapy could impact inflammatory processes in rheumatoid arthritis.
  • To consider future directions for antiadhesion therapies in treating inflammatory arthritis.

Main Methods:

  • Review of existing literature on adhesion receptors and their role in inflammation.

Related Experiment Videos

  • Discussion of antiadhesion therapy mechanisms, including blocking T cell recruitment and modulating immune cell function.
  • Examination of preclinical data from animal models of inflammatory arthritis.
  • Analysis of clinical trial data for antibodies targeting intercellular adhesion molecule-1 (ICAM-1) in rheumatoid arthritis.

    • Main Results:

    • Adhesion receptors are crucial for inflammatory cell trafficking and activation in rheumatoid arthritis.
    • Antiadhesion therapy shows promise in preclinical models by hindering inflammatory cell infiltration.
    • Inhibition of adhesion receptors may attenuate the function of immune cells within the inflamed synovium.
    • An antibody against intercellular adhesion molecule-1 (ICAM-1) has demonstrated utility in rheumatoid arthritis patient trials.

    Conclusions:

    • Adhesion receptors represent valuable therapeutic targets for systemic inflammatory diseases like rheumatoid arthritis.
    • Antiadhesion therapy offers a dual mechanism of action: preventing inflammatory cell entry and modulating existing immune cell activity.
    • Evidence from animal models and early clinical trials supports the potential of antiadhesion strategies in managing inflammatory arthritis.
    • Further research and development in antiadhesion therapies are warranted for treating rheumatoid arthritis and related conditions.